| Popis: |
Over the last decade, innovative treatments have enlarged the therapeutic arsenal against NSCLC. Although there is clinical evidence supporting treatment options, controversy surrounds the impact of their combinations and sequence. The goal of this study was to fill this gap using real world data (Symphony Health).9676 Patients with a diagnosis of non-metastatic (NM) and metastatic (M) NSCLC between July 2016 and December 2016 were included and followed till December 2021. The following data were collected: diagnostic date, age, gender, comorbidities, metastases, treatments (SUrgery, RAdiotherapy, CHemotherapy, IMmunotherapy, and TArgeted therapies), sequence (L1-L4), and death. Treatment patterns (Sankey graphs), and outcomes (Kaplan-Meyer and Cox regressions) were derived.Amongst NM patients, the most frequently observed treatments were RA, IM, IM and CH in first, second, third and fourth lines respectively. In M patients, the most frequent treatments were CH, IM, IM, and IM in first, second, third and fourth lines respectively. The overall 5-years survival in the cohort was 23.7 % (36 % in NM, 16 % in M). The corresponding median survival time were 1.98 years (3.2 NM, 1.27 M). In NM, best median survival times were recorded for those with only one line SU. For patients who had 2 lines, CH→IM; 3 lines, CH→IM→CH. In M, best median survival times were recorded for those with only one line RA. For patients who had 2 lines CH→IM; 3 lines CH→IM→CH.These new insights could guide further studies and improve the management of patients with NSCLC. |
